Voigtlaender Minna, Vogler Birthe, Trepel Martin, Panse Jens, Jung Roman, Bokemeyer Carsten, Bacher Ulrike, Binder Mascha
Department of Oncology and Hematology, Hubertus Wald Tumorzentrum/UCCH, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Ann Hematol. 2015 Sep;94(9):1559-65. doi: 10.1007/s00277-015-2409-9. Epub 2015 Jun 5.
Monoclonal B-cell lymphocytosis (MBL) and monoclonal gammopathy of undetermined significance (MGUS) result from clonal expansions of mature B or plasma cells. Here, we set out to determine the immunophenotypic/monoclonal immunoglobulin (M protein) features and co-prevalence of MBL and MGUS in a hospital-based cohort of 1909 non-hematooncological patients. Of the evaluable cases, 3.8 % showed evidence for MBL by immunophenotyping, while 9.8 % were screened positive for M protein by immunofixation. With six concomitant cases (0.4 %), MBL and MGUS were not statistically associated. At least in two of these coincident cases, MBL and MGUS were of different clonal origin since both clones had divergent light chain restriction. CD5(-) MBL (57.1 %) and IgM+ MGUS (24.7 %) were strikingly overrepresented compared to population-based screenings and did not progress to overt lymphoma or myeloma during the observation period (mean follow-up of 117 weeks or 110 weeks, respectively). Prevalence and phenotypes suggest that a substantial proportion of incidental MBL and MGUS in hospitalized patients may be attributed to transiently expanded B-cell clones in the context of disease-related immune stimulation rather than reflecting veritable precursors of clonal B-cell malignancies.
单克隆B细胞淋巴细胞增多症(MBL)和意义未明的单克隆丙种球蛋白病(MGUS)是成熟B细胞或浆细胞克隆性扩增的结果。在此,我们着手确定1909例非血液肿瘤患者的医院队列中MBL和MGUS的免疫表型/单克隆免疫球蛋白(M蛋白)特征及共患病率。在可评估病例中,3.8%通过免疫表型分析显示有MBL证据,而9.8%通过免疫固定法筛查M蛋白呈阳性。有6例同时存在(0.4%),MBL和MGUS无统计学关联。在这些合并病例中至少有两例,MBL和MGUS起源于不同的克隆,因为两个克隆具有不同的轻链限制性。与基于人群的筛查相比,CD5(-)MBL(57.1%)和IgM+MGUS(24.7%)显著增多,且在观察期内(分别平均随访117周或110周)未进展为明显的淋巴瘤或骨髓瘤。患病率和表型表明,住院患者中相当一部分偶然发现的MBL和MGUS可能归因于疾病相关免疫刺激背景下短暂扩增的B细胞克隆,而非反映克隆性B细胞恶性肿瘤的真正前体。